Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Arrhythmogenic right ventricular cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
2 Cell adhesion molecule (CAM) interaction 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
3 Cell adhesion molecule (CAM) interaction 💬
1件: PDCD1 💬 Pembrolizumab 💬 Pembrolizumab 3件: 25, 97, 285 💬
4 Coronavirus disease 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
5 Coronavirus disease 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
6 Cytokine-cytokine receptor interaction 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 30件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 63, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
7 Cytokine-cytokine receptor interaction 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
8 Cytokine-cytokine receptor interaction 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
9 Cytoskeleton in muscle cells 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
10 Dilated cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
11 ECM-receptor interaction 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
12 Epstein-Barr virus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
13 Epstein-Barr virus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
14 Focal adhesion 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
15 Hematopoietic cell lineage 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 30件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 63, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
16 Hematopoietic cell lineage 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
17 Hepatitis B 💬
1件: IFNAR1 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
18 Hepatitis B 💬
1件: IFNAR1 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
19 Hepatitis C 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
20 Hepatitis C 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
21 Herpes simplex virus 1 infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
22 Herpes simplex virus 1 infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
23 Human papillomavirus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
24 Human papillomavirus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
25 Human papillomavirus infection 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
26 Hypertrophic cardiomyopathy 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
27 IgSF CAM signaling 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
28 Influenza A 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
29 Influenza A 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
30 Integrin signaling 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
31 Intestinal immune network for IgA production 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
32 JAK-STAT signaling pathway 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 30件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 63, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
33 JAK-STAT signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
34 JAK-STAT signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
35 Kaposi sarcoma-associated herpesvirus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
36 Kaposi sarcoma-associated herpesvirus infection 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
37 Leishmaniasis 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
38 Leukocyte transendothelial migration 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
39 Measles 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
40 Measles 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
41 Natural killer cell mediated cytotoxicity 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
42 Natural killer cell mediated cytotoxicity 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
43 Necroptosis 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
44 Necroptosis 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
45 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Methylprednisolone 💬 Methylprednisolone 51件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 111, 127, 145, 162, 164, 211, 222, 223, 224, 271, 283, 284, 285, 296, 300 💬
46 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Methylprednisolone acetate 💬 Methylprednisolone 51件:  2 ,  6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 111, 127, 145, 162, 164, 211, 222, 223, 224, 271, 283, 284, 285, 296, 300 💬
47 Neuroactive ligand-receptor interaction 💬
1件: NR3C1 💬 Prednisolone 💬 Prednisolone 48件:  3 , 11, 13, 14, 18, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 54, 56, 57, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 111, 113, 145, 162, 222, 223, 251, 269, 271, 296, 299, 300 💬
48 NOD-like receptor signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
49 NOD-like receptor signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
50 Osteoclast differentiation 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
51 Osteoclast differentiation 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
52 Pathways in cancer 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 30件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 63, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
53 Pathways in cancer 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
54 Pathways in cancer 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
55 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: PDCD1 💬 Pembrolizumab 💬 Pembrolizumab 3件: 25, 97, 285 💬
56 PI3K-Akt signaling pathway 💬
1件: CSF3R 💬 Filgrastim 💬 Filgrastim 30件:  2 ,  6 , 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 47, 49, 51, 60, 62, 63, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
57 PI3K-Akt signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
58 PI3K-Akt signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
59 PI3K-Akt signaling pathway 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
60 Pyrimidine metabolism 💬
1件: DHODH 💬 Teriflunomide 💬 Teriflunomide 4件: 13, 25, 26, 63 💬
61 Regulation of actin cytoskeleton 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬
62 T cell receptor signaling pathway 💬
1件: PDCD1 💬 Pembrolizumab 💬 Pembrolizumab 3件: 25, 97, 285 💬
63 Toll-like receptor signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa 💬 Interferon alfa 5件: 25, 26, 28, 56, 96 💬
64 Toll-like receptor signaling pathway 💬
2件: IFNAR1, IFNAR2 💬 Interferon alfa-2b 💬 Interferon alfa-2b 2件: 25, 26 💬
65 Yersinia infection 💬
1件: ITGA4 💬 Natalizumab 💬 Natalizumab 5件: 13, 15, 25, 46, 96 💬